This Week in Cardiology

Latest Episodes:

May 02, 2025 This Week in Cardiology May 02, 2025

Show notes

The FDA approval of TAVR for asymptomatic AS, digital health, subcutaneous vs transvenous ICD, and cryptogenic stroke in young adults are discussed by John Mandrola, MD.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I FDA announces approval for TAVR in pts with asymptomatic AS

Edwards Press Release https://www.edwards.com/newsroom/news/2025-05-01-edwards-tavr-receives-fda-approval-for-patients-with-asymptomatic-severe-aortic-stenosis
Transcatheter Aortic-Valve Replacement for Asymptomatic Severe Aortic Stenosis (EARLY TAVR) https://www.nejm.org/doi/full/10.1056/NEJMoa2405880
EARLY TAVR: A Positive Trial That Fails to Inform Clinical Decisions https://www.medscape.com/viewarticle/early-tavr-positive-trial-fails-inform-clinical-decisions-2024a1000kec
Asymptomatic Aortic Stenosis: 'Time to Act' or Not So Fast? https://www.medscape.com/viewarticle/asymptomatic-aortic-stenosis-time-act-or-not-so-fast-2025a10005o9

II PPG that Can Distinguish source of Tachycardia

Machine-learning guided differentiation between photoplethysmography waveforms of supraventricular and ventricular origin https://doi.org/10.1016/j.cmpb.2025.108798

III PRAETORIAN -XL trial

Device-related Complications in Transvenous Versus Subcutaneous Defibrillator Therapy During Long-term Follow-up: the PRAETORIAN-XL Trial https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.074576
Subcutaneous or Transvenous Defibrillator Therapy (PRAETORIAN trial) https://www.nejm.org/doi/full/10.1056/NEJMoa1915932
Subcutaneous or Transvenous Defibrillator Therapy Letter to Editor https://www.nejm.org/doi/full/10.1056/NEJMc2034917
The PRAETORIAN Trial: Guarded Approach to Subcutaneous ICD Best https://www.medscape.com/viewarticle/937156

IV Stroke in Young People

Burden of Modifiable Risk Factors in Young-Onset Cryptogenic Ischemic Stroke by High-Risk Patent Foramen Ovale https://www.ahajournals.org/doi/10.1161/STROKEAHA.124.049855
Migraine: A Key Factor in Young Adults With Unexplained Stroke https://www.medscape.com/viewarticle/migraine-key-factor-young-adults-unexplained-stroke-2025a10009jj
U.S. stroke rate declining in adults 75 and older, yet rising in adults 49 and younger ASA statement https://newsroom.heart.org/news/u-s-stroke-rate-declining-in-adults-75-and-older-yet-rising-in-adults-49-and-younger
Increasing stroke in the young https://doi.org/10.1016/j.ajpc.2020.100085

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Apr 25 2025 This Week in Cardiology Apr 25, 2025

Show notes

AI and ECGs, novel ways to treat hypertension, combined lipid-lowering therapy after myocardial infarction, PFA and silent stroke, a move toward accountability in AF ablation, and pacing issues in TTVR are the topics John Mandrola, MD, discusses in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I Help with ECGs in the ED

AI Shows Promise for Rapid NSTEMI Diagnosis

https://www.medscape.com/viewarticle/ai-shows-promise-rapid-nstemi-diagnosis-2025a10009pw

Buscher et al https://doi.org/10.1093/eurheartj/ehaf254

II A Novel way to Treat HTN

A Pacemaker to Control BP Gets FDA Breakthrough Designation

https://www.medscape.com/viewarticle/pacemaker-control-bp-gets-fda-breakthrough-designation-2025a10009t3

JAHA paper https://www.ahajournals.org/doi/10.1161/JAHA.120.020492
Backbeat https://clinicaltrials.gov/study/NCT06059638

III Type of PFA may matter for Silent Cerebral Lesions

Paper https://www.ahajournals.org/doi/10.1161/CIRCEP.125.013719

IV Accountability coming to US AF ablation

Heart Rhythm Society Releases a Document on Establishing Centers of Excellence for AF ablation -- Press Release https://www.hrsonline.org/news/new-white-paper-on-atrial-fibrillation-centers-of-excellence/

V Pacing in Patients with Undergoing Transcatheter Tricuspid Valve Replacement

Paper https://doi.org/10.1016/j.hrthm.2025.02.004

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Apr 18 2025 This Week in Cardiology Apr 18, 2025

Show notes

The FAME 3 trial 5-year results, TAVR at 5 years, pacers after TAVR, and mavacamten not a wonder drug are the topics John Mandrola, MD, discusses in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I FAME 3 at Five Years

Stents as Good as Surgery for Triple-Vessel Disease https://www.medscape.com/viewarticle/noninvasive-stents-good-surgery-triple-vessel-disease-2025a10007l4

Main trial NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2112299
Circulation 3-years https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.065770
5-year results Lancet 10.1016/S0140-6736(25)00505-7 https://linkinghub.elsevier.com/retrieve/pii/S0140673625005057

II TAVR in Low-Risk Patients at 5 years

5-Year TAVR, Surgery Outcomes Similar in Low-Risk Patients

https://www.medscape.com/viewarticle/5-year-tavr-surgery-outcomes-similar-low-risk-patients-2025a10007zl

EVOLUT Low-Risk 5 years https://www.jacc.org/doi/10.1016/j.jacc.2025.03.004
EVOLUT Editorial – We're Halfway There https://www.jacc.org/doi/10.1016/j.jacc.2025.03.428
PARTNER 3 Low-Risk https://www.nejm.org/doi/full/10.1056/NEJMoa2307447
NOTION at 5 years https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.036606

III The Matter of Pacemakers After TAVI

JACC IV Study Badertscher https://www.jacc.org/doi/10.1016/j.jcin.2025.03.028
Assessing the quality of reporting of harms in randomized controlled trials published in high impact cardiovascular journals

IV Mavacamten Looks to Have Specific Indications

EXPLORER HCM 10.1016/S0140-6736(20)31792-X External Link
VALOR HCM https://jamanetwork.com/journals/jamacardiology/fullarticle/2809050
BMS Press Release https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Provides-Update-on-Phase-3-ODYSSEY-HCM-Trial/

FINAL THOUGHTS

PRAGUE 25 https://bmjopen.bmj.com/content/12/6/e056522

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

April 11, 2025 This Week in Cardiology Podcast Apr 11, 2025

Show notes

The TAP-IT, STRIDE, FreshUP, and SINGLE SHOT CHAMPION trials are discussed by John Mandrola, MD, in this week's podcast.

This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic

I TAP IT

TAP IT trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.124.073521

II STRIDE

LANCET Ref 10.1016/S0140-6736(25)00509-4

SUMMIT HF https://www.nejm.org/doi/full/10.1056/NEJMoa2410027

III FRESH UP

No Need to Restrict Fluids in Stable Heart Failure

https://www.medscape.com/viewarticle/no-need-restrict-fluids-stable-heart-failure-2025a10008bu

Nature (Trial) https://www.nature.com/articles/s41591-025-03628-4

SODIUM HF https://pubmed.ncbi.nlm.nih.gov/35381194/

IV PFA for AF ablation

SINGLE SHOT CHAMPION https://www.nejm.org/doi/full/10.1056/NEJMoa2502280

ADVENT https://www.nejm.org/doi/full/10.1056/NEJMoa2307291

Foy et al https://pmc.ncbi.nlm.nih.gov/articles/PMC11852674/

MANIFEST REDO Study https://doi.org/10.1093/europace/euaf012

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Apr 04 2025 This Week in Cardiology Apr 04, 2025

Show notes

Trials from the 2025 American College of Cardiology scientific sessions, including the WARRIOR, PROTECT TAVI, DAPATAVI, and SOUL are reviewed by John Mandrola, MD

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I Thank you Comments

II WARRIOR Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD

Keep Fighting INOCA After Neutral WARRIOR Trial https://www.medscape.com/viewarticle/keep-fighting-inoca-after-neutral-warrior-trial-2025a10007uf

III Cerebral Embolic Protection in TAVI

PROTECT TAVI https://www.nejm.org/doi/full/10.1056/NEJMoa2415120
PROTECTED TAVR https://www.nejm.org/doi/full/10.1056/NEJMoa2204961
Instrumental Variables in Randomized Trials https://evidence.nejm.org/doi/10.1056/EVIDctw2400204

IV DAPATAVI

SGLT2 Inhibitors Progressing to New Standard After TAVI https://www.medscape.com/viewarticle/sglt2-inhibitors-progressing-new-standard-after-tavi-2025a100081y

Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation https://www.nejm.org/doi/full/10.1056/NEJMoa2500366

V SOUL Study of Oral Semaglutide and CV outcomes in Diabetes

Oral GLP-1 Receptor Agonist Reduces CV Risk https://www.medscape.com/viewarticle/oral-glp-1-receptor-antagonist-reduces-cv-risk-2025a10007kr

Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes https://www.nejm.org/doi/full/10.1056/NEJMoa2501006

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Mar 28 2025 This Week in Cardiology Mar 28, 2025

Show notes

Stopping oral anticoagulation after AF ablation, the core problem with paradoxes like the smoker's paradox, chronic total occlusion PCI, and an ACC/EHRA preview are discussed by John Mandrola, MD, in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I Oral Anticoagulation after Successful AF Ablation

Iwawakie et al https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2831851
OCEAN protocol paper https://doi.org/10.1016/j.ahj.2017.12.007

II Smoker's Paradox

Presch et al https://www.jacc.org/doi/10.1016/j.jcin.2024.12.028
Gupta et al https://doi.org/10.1161/JAHA.116.003370

III CTO PCI

Main sub-analysis paper Bangalore et al https://doi.org/10.1016/j.jacc.2025.01.029
DECISION CTO https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.031313
Main EURO CTO trial https://doi.org/10.1093/eurheartj/ehy220
3-year MACE of EURO CTO https://eurointervention.pcronline.com/article/three-year-outcomes-of-eurocto-a-randomized-multicentre-trial-comparing-revascularization-and-optimal-medical-therapy-for-chronic-total-coronary-occlusions
EXPLORE https://www.jacc.org/doi/abs/10.1016/j.jacc.2016.07.744
ISCHEMIA CTO https://www.clinicaltrials.gov/study/NCT03563417

IV ACC and EHRA Preview

Mandrola's 5 Trials to Look for at the 2025 American College of Cardiology Scientific Sessions https://www.medscape.com/viewarticle/mandrolas-5-trials-look-2025-american-college-cardiology-2025a10006zu

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Mar 21 2025 This Week in Cardiology Mar 21, 2025

Show notes

A large trial in cardiac pacing finally published, PVCs and cardiomyopathy, cannabis, CV risk and the danger of observational studies, and the tale of two disparate statin trials are the topics John Mandrola, MD, discusses in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I BioPace Trial

Trial manuscript https://doi.org/10.1093/europace/euaf029

II Another Belief Challenged in EP this week—PVCs and CM '

UC Paper https://doi.org/10.1016/j.jacep.2025.01.004
JACC Review https://doi.org/10.1016/j.jacc.2024.03.416
Lee et al https://heart.bmj.com/content/105/18/1408

III Cannabis and CV Risk

Cannabis and MACE in JACC Advances: https://www.jacc.org/doi/10.1016/j.jacadv.2025.101698
Zeraatkar –Grilling the data https://doi.org/10.1016/j.jclinepi.2024.111278
PLOS-1 10.1371/journal.pone.0199705

IV Cardio-oncology

Jacc Onc Substdy https://www.jacc.org/doi/10.1016/j.jaccao.2024.11.008
Editorial https://www.jacc.org/doi/10.1016/j.jaccao.2025.01.006
STOP CA JAMA 2023 https://jamanetwork.com/journals/jama/fullarticle/2807988
PREVENT https://evidence.nejm.org/doi/10.1056/EVIDoa2200097

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Mar 14 2025 This Week in Cardiology Mar 14, 2025

Show notes

Listener feedback, resistant hypertension, K-binders for MRA use in heart failure, nutritional epidemiology, and a positive study for vitamin D are the topics John Mandrola, MD, discusses in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I Listener Feedback

Califf editorial https://www.jacc.org/doi/10.1016/j.jaccas.2020.01.003

II Resistant HTN

Positive Topline Results for Lorundrostat in Hypertension

https://www.medscape.com/viewarticle/positive-topline-results-lorundrostat-hypertension-2025a100062e

III K-Binding

REALIZE K Trial https://doi.org/10.1016/j.jacc.2024.11.014
Packer Editorial https://doi.org/10.1016/j.jacc.2025.01.011
Diamond Trial EHJ https://doi.org/10.1093/eurheartj/ehac401
REALIZE K Commentary https://www.medscape.com/viewarticle/realize-k-new-potassium-binder-help-keep-spiro-board-2024a1000m2c

IV Butter vs Plant-based Oils and Mortality

JAMA-IM Study https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2831265
Is Red Meat Healthy? Multiverse Analysis Has Lessons Beyond Meat https://www.medscape.com/viewarticle/red-meat-healthy-multiverse-analysis-has-lessons-beyond-meat-2024a10008qv
Cookbook Review https://doi.org/10.3945/ajcn.112.047142

V Vitamin D

Impact Factor https://www.medscape.com/viewarticle/rare-win-vitamin-d-this-time-ms-2025a10005ul
D-Lay trial https://jamanetwork.com/journals/jama/fullarticle/2831270

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Mar 07 2025 This Week in Cardiology Mar 07, 2025

Show notes

Listener feedback on asymptomatic aortic stenosis (AS), transcatheter aortic valve replacement (TAVR) vs surgical aortic valve replacement (SAVR), coronary artery calcium (CAC), and revascularization for patients with ischemic LV dysfunction are discussed by John Mandrola, MD, in today's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I Aortic Valve Intervention for Asymptomatic AS

Asymptomatic Aortic Stenosis: "Time to Act" or Not So Fast?

https://www.medscape.com/viewarticle/asymptomatic-aortic-stenosis-time-act-or-not-so-fast-2025a10005o9

EARLY TAVR: A Positive Trial That Fails to Inform Clinical Decisions

https://www.medscape.com/viewarticle/early-tavr-positive-trial-fails-inform-clinical-decisions-2024a1000kec

Reddy et al: https://doi.org/10.1016/j.jacc.2024.12.031
Wallach editorial https://doi.org/10.1016/j.jacc.2025.01.020
Guerrero https://www.tctmd.com/slide/tavr-young-patients-current-treatment-patterns-us

II CAC - Coronary Artery Calcium

Coronary Artery Calcium Testing—Too Early, Too Late, Too Often https://jamanetwork.com/journals/jamacardiology/fullarticle/2830950

CAUGHT-CAD https://jamanetwork.com/journals/jama/fullarticle/2831115

III CABG, PCI or Meds for Ischemic LV Dysfunction

STICH https://www.nejm.org/doi/full/10.1056/NEJMoa1100356
STICHES https://www.nejm.org/doi/full/10.1056/NEJMoa1602001
REVIVED BCIS https://www.nejm.org/doi/full/10.1056/NEJMoa2206606
EHJ paper https://doi.org/10.1093/eurheartj/ehaf080

IV Preview

https://www.medscape.com/viewarticle/shed-lead-and-injuries-should-cath-labs-go-lead-free-2024a1000hnb

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Feb 28 2025 This Week in Cardiology Feb 28, 2025

Show notes

The treatment of asymptomatic aortic stenosis, the move to composite endpoints in trials, IFR vs FFR and high-frequency low tidal volume ventilation for AF ablation are the topics John Mandrola, MD, discusses in today's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I Aortic valve intervention for Asymptomatic AS

Lindman editorial https://jamanetwork.com/journals/jamacardiology/fullarticle/2829881
Trends https://pmc.ncbi.nlm.nih.gov/articles/PMC11308430/
Podcast EARLY TAVR Nov 8, 2024 This Week in Cardiology Podcast https://www.medscape.com/viewarticle/1001865
Faith Healing and Subtraction Anxiety https://www.ahajournals.org/doi/10.1161/circoutcomes.118.004665
Early TAVR trial https://www.nejm.org/doi/10.1056/NEJMoa2405880
EVOLVED https://jamanetwork.com/journals/jama/fullarticle/2825540
AVATAR https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.057639

II Trial Endpoints

Shepshelovich https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2830023
Brown meta-analysis https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2785560

III IFR vs FFR—a debate b/w RCTs and observational data

5-year DEFINE https://jamanetwork.com/journals/jamacardiology/fullarticle/2824470
5-year SwedeHeart IFR https://doi.org/10.1016/j.jacc.2021.12.030
Eftekhari meta-analysis https://doi.org/10.1093/eurheartj/ehad582
Gotberg SWEDEHEART Registry https://doi.org/10.1016/j.jcin.2024.12.003
Editorial of SWEDEHEART-Registry https://doi.org/10.1016/j.jcin.2024.12.014

IV High-frequency low-tidal-volume ventilation for AF ablation

Osorio et al https://doi.org/10.1016/j.hrthm.2024.07.094

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected